Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy by Botelho, MG et al.
Title Arginine Metabolism in Bacterial Pathogenesis and CancerTherapy
Author(s) Xiong, L; Teng, LL; Botelho, MG; Lo, CLR; Lau, SKP; Woo, PCY
Citation International Journal of Molecular Sciences, 2016, v. 17, p. 363
Issued Date 2016
URL http://hdl.handle.net/10722/223840
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 International Journal of 
Molecular Sciences
Review
Arginine Metabolism in Bacterial Pathogenesis and
Cancer Therapy
Lifeng Xiong 1,†, Jade L. L. Teng 1,2,3,†, Michael G. Botelho 4, Regina C. Lo 5,6,
Susanna K. P. Lau 1,2,3,7,* and Patrick C. Y. Woo 1,2,3,7,*
1 Department of Microbiology, The University of Hong Kong, Hong Kong, China; lfxiong@hku.hk (L.X.);
llteng@hku.hk (J.L.L.T.)
2 Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong, China
3 State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, China
4 Faculty of Dentistry, The University of Hong Kong, Hong Kong, China; botelho@hku.hk
5 Department of Pathology, The University of Hong Kong, Hong Kong, China; reginalo@pathology.hku.hk
6 State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China
7 Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong, China
* Correspondence: skplau@hku.hk (S.K.P.L.); pcywoo@hku.hk (P.C.Y.W.);
Tel.: +852-2255-4892 (S.K.P.L. & P.C.Y.W.); Fax: +852-2255-1241 (S.K.P.L. & P.C.Y.W.)
† These authors contributed equally to this work.
Academic Editor: Helmut Segner
Received: 29 December 2015; Accepted: 4 March 2016; Published: 11 March 2016
Abstract: Antibacterial resistance to infectious diseases is a significant global concern for health
care organizations; along with aging populations and increasing cancer rates, it represents a great
burden for government healthcare systems. Therefore, the development of therapies against bacterial
infection and cancer is an important strategy for healthcare research. Pathogenic bacteria and cancer
have developed a broad range of sophisticated strategies to survive or propagate inside a host and
cause infection or spread disease. Bacteria can employ their own metabolism pathways to obtain
nutrients from the host cells in order to survive. Similarly, cancer cells can dysregulate normal human
cell metabolic pathways so that they can grow and spread. One common feature of the adaption
and disruption of metabolic pathways observed in bacterial and cancer cell growth is amino acid
pathways; these have recently been targeted as a novel approach to manage bacterial infections
and cancer therapy. In particular, arginine metabolism has been illustrated to be important not
only for bacterial pathogenesis but also for cancer therapy. Therefore, greater insights into arginine
metabolism of pathogenic bacteria and cancer cells would provide possible targets for controlling
of bacterial infection and cancer treatment. This review will summarize the recent progress on the
relationship of arginine metabolism with bacterial pathogenesis and cancer therapy, with a particular
focus on arginase and arginine deiminase pathways of arginine catabolism.
Keywords: arginine metabolism; arginase; arginine deiminase; bacterial pathogenesis; cancer therapy
1. Introduction
Globally, infections and cancers are two of the leading causes of death. Bacterial infections
are among the most extensively studied conditions as bacteria have established a broad range
of sophisticated strategies to adapt to various environmental stresses and can resist some of the
host defenses, such as chemical bactericidal components, phagocytosis (innate), and other immune
(adaptive) responses [1,2]. The versatile ability of bacteria to resist host defenses allows bacteria
to survive in an infection and promote their own life cycle through replication and spread in host
cells [2]. With the recognition of the metabolic differences between normal cells and tumor cells, the
therapeutic targeting of the cellular metabolism of cancer cells is an increasing field of research for
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cancer therapy [3,4]. The active deprivation of amino acids inside tumor cells, which are auxotrophic
for these amino acids, has been recognized as one of the novel approaches for cancer therapy [5].
In this review, we will summarize the recent progress on the relationship of arginine metabolism
with bacterial pathogenesis and cancer therapy, with a particular focus on the arginase and arginine
deiminase (ADI) pathways of arginine catabolism.
2. Arginine Metabolism and Bacterial Pathogenesis
L-arginine is categorized as a conditionally essential amino acid in human beings. This is because
it is possible to derive arginine by de novo biosynthesis and absorption from consumed diet [6].
In addition, L-arginine is a metabolically flexible amino acid and is metabolically interconvertible with
a range of amino acids such as proline and glutamate. L-arginine is also involved in the synthesis of
metabolites such as nitric oxide, creatine, polyamines, agmatine, and metabolites of the urea cycle in
the cellular metabolic pathways [4,7,8].
2.1. Arginase Pathway and Bacterial Pathogenesis
2.1.1. Arginase Pathway
The arginase enzyme and its associated pathway is one arm of arginine catabolism. The arginase
pathway hydrolyzes arginine to urea and ornithine, which is then hydrolyzed by ornithine
aminotransferase (RocD) and ∆-pyrroline-5-carboxylate dehydrogenase (RocA) respectively, with
the production of glutamate [7] (Figure 1). Bacillus subtilis is one of the most studied bacteria for
examining the arginase pathway, and is the only pathway of arginine catabolism in B. subtilis, with
the production of intermediaries (Figure 1) that can be broken down as a source of nitrogen [9].
In B. subtilis, rocABC [10] and rocDEF [11] operons and the rocG gene [12], are responsible for producing
proteins of the arginase pathway. Arginase is encoded by gene rocF in B. subtilis and is responsible for
catalyzing the first step of the arginase pathway to catabolize arginine [7]. The product from this step
(ornithine) is then hydrolyzed by ornithine aminotransferase (RocD) and ∆-pyrroline-5-carboxylate
dehydrogenase (RocA), respectively, with the production of glutamate (Figure 1). rocC and rocE encode
arginine permeases and RocB probably function as a citrullinase [11,13]. Glutamate can be further
catabolized by glutamate dehydrogenase (GDH), which is encoded by rocG gene, with the production
of 2-ketoglutarate. Some bacteria employ this pathway to consume arginine and function as the
supplier of carbon and/or nitrogen source. For example, if the bacteria also contain the urease system,
the byproduct of urea from this pathway could be further catalyzed to ammonia and used as nitrogen
source [7]. The genes from the arginase pathway of bacteria and their corresponding products are
summarized in Table 1. In addition, their counterparts with similar catabolic function or homologue in
mammalian cells (if any) are also listed.
Int. J. Mol. Sci. 2016, 17, 363 3 of 18
Int. J. Mol. Sci. 2016, 17, 363 3 of 18 
 
 
Figure 1. Simplified model for bacterial arginine catabolism by arginase and ADI pathways. In 
bacteria, arginine could be catalyzed by the arginase pathway (in blue) and/or the ADI pathway (in 
light salmon). For the arginase pathway, arginine is converted into urea and ornithine, which is 
subsequently catalyzed into glutamate. The ADI pathway catabolizes arginine to ornithine with the 
byproducts of ammonia, CO2 and ATP. The produced ornithine could be transported outside and 
exchange one molecule of arginine in the cell by the arginine–ornithine antiporter (ArcD) located in 
the bacterial membrane. Arginine may also be transported by some unknown transporters, which 
are shown by the question mark. RocD: ornithine aminotransferase; RocF: arginase; RocA: 
Δ-pyrroline-5-carboxylate dehydrogenase; ArcC: carbamate kinase; ArcA: arginine deiminase; ArcB: 
ornithine carbamoyltransferase; Pi: inorganic phosphate. 
Table 1. The genes from arginase and ADI pathway of bacteria and counterparts in mammalian cells 
with homologue or similar function. 
Pathway  
(Genes) Products 
Counterparts in Mammalian Cells  
(with Similar Function or 
Homologue) 
Source/ 
Reference 
The arginase pathway 
rocA 
Pyrroline-5-carboxylate 
dehydrogenase 
Pyrroline-5-carboxylate 
dehydrogenase 
[10] 
rocB Probable citrullinase - [13] 
rocC Arginine permease Arginine permease-like [11,13] 
rocD Ornithine aminotransferase (OAT) Ornithine aminotransferase [11] 
rocE Arginine permease Arginine permease-like [11,13] 
rocF Arginase Arginase I and II [11] 
The ADI pathway 
arcA Arginine deiminase Nitric oxide synthase (NOS) [14–18] 
arcB Ornithine carbamoyltransferase Ornithine carbamoyltransferase [14,18] 
arcC Carbamate kinase Carbamate kinase-like [15,16] 
arcD Arginine-ornithine antiporter - [16–18] 
  
Figure 1. Simplified model for bacterial arginine catabolism by arginase and ADI pathways.
In bacteria, arginine could be catalyzed by the arginase pathway (in blue) and/or the ADI pathway
(in light salmon). For the arginase pathway, arginine is converted into urea and ornithine, which is
subsequently catalyzed into glutamate. The ADI pathway catabolizes arginine to ornithine with the
byproducts of a onia, CO2 and ATP. The produced ornithine could be transported outside and
exchange one olecule of arginine in the cell by the arginine–ornithine antiporter (ArcD) located
in the bacterial embrane. Arginine may also be transported by some unknown transporters,
which are shown by the question mark. RocD: ornithine aminotransferase; RocF: arginase; Roc :
∆-pyrroline-5-carboxylate dehydrogenase; rc : carba ate kinase; rc : arginine dei inase; rcB:
or it i e carba oyltra sferase; i: i orga ic os ate.
Table 1. The genes fro arginase and ADI pathway of bacteria and counterparts in a alian cells
ith ho ologue or si ilar function.
Pathway
(Genes) Products
Counterparts in Mammalian
Cells (with Similar Function or
Homologue)
Source/
Reference
The arginase pathway
rocA Pyrroline-5-carboxylatedehydrogenase
Pyrroline-5-carboxylate
dehydrogenase [10]
rocB Probable citrullinase - [13]
rocC Arginine permease Arginine permease-like [11,13]
rocD Ornithine aminotransferase (OAT) Ornithine aminotransferase [11]
rocE Arg ine permease Argin e permease-like [11,13]
rocF Arginase Arginase I and II [11]
I t ay
arcA Arginine deiminase Nitric oxide synthase (NOS) [14–18]
arcB Ornithine carbamoyltransferase Ornithine carbamoyltransferase [14,18]
arcC Carbamate kinase Carbamate kinase-like [15,16]
arcD Arginine-ornithine antiporter - [16–18]
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2.1.2. Regulation of Arginase Pathway
Gene expression can be regulated at different stages including transcription, post-transcription,
translation, and post-translation. However, the most generally used mechanism of gene regulation in
bacteria lies at the transcriptional level [19], and proper transcriptional regulation is crucial for bacteria
to respond to varied environmental niches [20]. The transcriptional regulation occurs by binding to the
promoter regions in induction or repression manner [19], which could be mediated by transcription
factors, environmental stresses, and some other effectors.
Regulation of the arginase pathway has also been well studied in B. subtilis. Both rocABC and
rocDEF operons, encoding enzymes for the arginase pathway, have similar promoter elements [10,11],
and their transcription is driven by a specialized protein (sigma factor) encoded by the sigL gene,
which has the same function as that of protein sigma 54 in Gram-negative bacteria [21]. In addition, the
transcription of rocABC and rocDEF operons promoters is positively regulated by the regulator RocR,
which is a transcriptional regulator from the protein family of NtrC/NifA, with a molecular weight of
52 kDa [7,10,13]. RocR functions by binding to enhancer-like elements (upstream activating sequences,
UASs) of promoter regions of rocABC and rocDEF operons [13]. The expression of rocR is negatively
autoregulated as the N-terminal part of RocR is an intramolecular repressor domain, and deletion of
this domain makes the constitutive expression of the roc operons [11,13]. Furthermore, the expression
of rocABC and rocDEF operons is also affected by another regulator named AhrC [13,22]. AhrC is a
homologous molecule to the arginine transcriptional regulator ArgR in Escherichia coli, which usually
binds to the promoter regions of target genes [11,13,22,23]. Similarly, it was shown that AhrC can bind
to the promoter region of rocA in a footprinting experiment [22]. Interestingly, it was proposed in
another study that AhrC should function by direct protein–protein interaction with RocR [13]. Besides,
the expression of the rocDEF operon was also observed to be induced by the presence of arginine,
ornithine, or proline in different environmental niches [11,13].
2.1.3. The Relationship between the Arginase Pathway and Bacterial Pathogenesis
Arginine is the common substrate of arginase and inducible type 2 nitric oxide synthase (NOS2 or
iNOS), which can be catabolized by arginase to ornithine and urea (Figure 1) or oxidized by iNOS to
L-citrulline and nitric oxide (NO) (Figure 2) [24]. Therefore, arginase is well studied for competing
with the NOS enzymes for substrate of arginine, thereby limiting NO production by different research
groups [8,24]. Besides the substrate competition, arginase was also observed to inhibit iNOS expression
at the translation level, thereby limiting NO production [8]. NO is a crucial element of innate immunity
and is one of the valuable antimicrobials of the host’s first line of defense [25,26]. Pathogenic bacteria
have developed different strategies targeting arginine for self-preservation. Similar to the arginase of
mammalian cells, the arginase produced by bacteria can also compete with iNOS of host cells for the
common substrate (arginine), thereby inhibiting the NO production and facilitating evasion of the host
defense system [27,28]. The competition between arginase and iNOS has been reported to affect the
outcome of infection of several pathogenic bacteria by modulating the NO production [29]. Among
these pathogenic bacteria, one of the extensively studied examples is Helicobacter pylori, which releases
its arginase to downregulate eukaryotic NO production so as to evade the host immune response,
thereby serving as a strategy for bacterial survival [7,28]. The arginase of H. pylori was observed
to resist acidic conditions in vitro and in macrophages, thereby reducing antibacterial effects [28,30].
Furthermore, arginase was employed by H. pylori to deplete L-arginine in macrophages, thereby
limiting NO production and prolonging bacterial survival. Deletion of the rocF gene that is responsible
for arginase production significantly increased NO production and thereby decreased the survival
of the rocF gene mutant strain in macrophages [28,31]. However, the survival of rocF gene deleted
H. pylori was not affected in the macrophages from iNOS´{´ mice, indicating the survival decrease in
arginase-deficient H. pylori was NO-dependent. In addition, arginase from H. pylori also represses the
expression of the TCR ζ (CD3ζ) chain, thereby restraining the function of the host T cells, which can
also contribute to bacterial survival during Helicobacter infection [32].
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Figure 2. Proposed model for intracellular killing of bacteria by phagocyte and bacterial defense 
strategies against phagocytosis. Bacteria could be engulfed by a phagocyte into the phagosome (1), 
followed by fusion with a lysozyme to form a phagolysosome (2), being killed by varied strategies 
like pH decrease, enzymes (solid blue oval) release (2a), and production of antimicrobial NO by 
iNOS (2b). We propose that the bacteria containing ADI pathway genes may employ this pathway to 
defend these killing strategies in the following ways: firstly, the production of ammonia could 
probably raise the cytoplasmic pH, thereby inhibiting the formation of phagolysosome (3); secondly, 
the ADI pathway competes with iNOS for the common substrate (arginine), thereby reducing NO 
production (4); thirdly, arginine depletion would also activate the autophagy and/or apoptosis 
pathways, like that in cancer cells (Figure 3), to induce programmed cell death and release bacteria 
(5). 
H. pylori were found to upregulate arginase (arginase II) in RAW 264.7 macrophage cell lines, in 
a mouse model, and in human gastritis tissues. This upregulation was found to induce apoptosis. 
The action of arginase on arginine can produce an intermediary spermine, with the help of ornithine 
decarboxylase and spermine synthase. This is used by H. pylori to repress the expression of 
pro-inflammatory cytokines and iNOS, thereby preventing the antimicrobial effects of NO and the 
immune response in stimulated macrophages [33]. Of note, it was shown that host arginase 
(arginase II), which was upregulated to reduce NO production, can increase bacterial survival in 
Salmonella-infected macrophages [34]. Arginase has also been shown to be involved in bacterial 
infection caused by Mycobacterium tuberculosis [35,36], parasitic infection caused by Trypanosoma cruzi 
[37], and fungal infection caused by Candida albicans [38], implying the critical role of arginase for 
other infections. 
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cells (Figure 3), to induce programmed cell death and release bacteria (5).
H. pylori were found to upregulate arginase (arginase II) in RAW 264.7 macrophage cell lines,
in a mouse model, and in human gastritis tissues. This upregulation was found to induce apoptosis.
The action of arginase on arginine can produce an intermediary spermine, with the help of ornithine
decarboxylase and spermine synthase. This is used by H. pylori to repress the expression of
pro-inflammatory cytokines and iNOS, thereby preventing the antimicrobial effects of NO and the
immune response in stimulated macrophages [33]. Of note, it was shown that host arginase (arginase II),
which was upregulated to reduce NO production, can increase bacterial survival in Salmonella-infected
macrophages [34]. Arginase has also been shown to be involved in bacterial infection caused by
Mycobacterium tuberculosis [35,36], parasitic infection caused by Trypanosoma cruzi [37], and fungal
infection caused by Candida albicans [38], implying the critical role of arginase for other infections.
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depletion by ADI or arginase would induce a quick response of cell autophagy by the mammalian 
Target of Rapamycin (mTOR) or MEK-ERK pathway. Autophagy could recycle limited arginine and 
prevent apoptosis as a survival response in the short term. Instead, in long-term arginine 
deprivation, autophagy would contribute to caspase-independent (CASP-IND) cell death and 
caspase dependent (CASP-DEP) apoptosis could also happen. The dashed lines ( and  ) means 
the reactions are dependent on the availability of enzymes (panel A) or the reactions have not yet 
confirmed by experiments (panel B). MEK: mitogen-activated protein kinase, also known as 
extracellular signal-regulated kinase kinase; ERK: extracellular signal-regulated kinase. 
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[14–17,39,40]. As one of the most important arginine catabolism pathways, the ADI pathway is a 
multi-enzyme pathway encoded by arc operons genes named arcA, arcB, and arcC [15,39], which 
hydrolyze arginine to ornithine, with the byproducts of ammonia, CO2 and ATP. Generally, arginine 
is first catabolized to citrulline by arcA-encoded ADI, which is further hydrolyzed to ornithine and 
carbamoyl phosphate via an arcB-encoded catabolic ornithine carbamoyltransferase (OTC). Finally, 
a phosphate is relocated from carbamoyl phosphate to adenosine diphosphate (ADP), by an 
arcC-encoded enzyme named carbamate kinase (CK), with the production of ammonia, carbon 
dioxide, and ATP. The production of ammonia by the ADI pathway could further produce NH4+ 
and thus increase the cytoplasmic pH, thereby protecting the bacteria from being killed by the 
Figure 3. Schematic representation of argininosuccinate synthetase (ASS)-negative cell death induced
by arginine deprivation. In ASS-negative cells, arginine cannot synthesize so arginine depletion by ADI
or arginase would induce a quick response of cell autophagy by the mammalian Target of Rapamycin
(mTOR) or MEK-ERK pathway. Autophagy could recycle limited arginine and prevent apoptosis
as a survival response in the short term. Instead, in long-term arginine deprivation, autophagy
would contribute to caspase-independent (CASP-IND) cell death and caspase dependent (CASP-DEP)
apoptosis could also happen. The dashed lines (
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dioxide, and ATP. The production of ammonia by the ADI pathway could further produce NH4+ and
thus increase the cytoplasmic pH, thereby protecting the bacteria from being killed by the hostile
acidic conditions [15]. Furthermore, the production of ATP can provide energy for bacteria to pump
cytoplasmic protons and maintain cytosolic pH homeostasis [15]. Another element of this pathway,
an arginine–ornithine antiporter (ArcD) encoding by arcD, could transport ornithine out and exchange
a molecule of arginine into the cell (Figure 1) [14,15,18]. The genes from the ADI pathway of bacteria
and corresponding products are summarized in Table 1. Their counterparts with similar catabolic
function or homologue in mammalian cells (if any) are also listed.
2.2.2. Regulation of Arginine Deiminase Pathway
As stated in Section 2.1.2, the most extensively studied regulatory mechanism of the ADI
pathway also lies at the transcriptional level, which is mediated by the transcriptional regulator
ArgR [9,15,17]. ArgR could be derived from two different protein families: ArgR/AhrC [41–43] and
AraC/XylS [9,44,45]. Irrespective of the family origin, ArgR proteins generally elicit their regulatory
role by binding to the ARG operator (ARG box) located in the arc operon promoter [46,47], via a
conserved helix-turn-helix motif in the C-terminal of ArgR [48]. Generally, ArgR regulator activates the
expression of ADI pathway genes in their individual bacteria [15,17,45,46,49]; the only exception is the
ArgR of Laribacter hongkongensis, a novel beta proteobacterium associated with gastroenteritis [50,51],
which has been illustrated to have dual regulatory functions on two adjacent arc operons within
L. hongkongensis [52].
Besides the transcriptional regulation by ArgR, ADI pathway genes are also affected by a variety
of environmental stresses. Firstly, the expression of ADI pathway genes are established to be activated
by anaerobicity in different bacteria [53], such as Pseudomonas aeruginosa, Bacillus licheniformis, and
Streptococcus suis, mediated by transcriptional regulators from the protein family of Crp/Fnr [54–56].
In enteric anaerobic bacteria, regulators from the Crp/Fnr family recognize conserved Crp/Fnr
DNA-binding sites located in the arc operon promoter [57,58], enabling them to function as a
transcriptional activator. Furthermore, carbon catabolite repression (CCR) has also been demonstrated
on the expression of ADI pathway genes in various bacteria [40,56,59,60]. In these bacteria, the
expression of arc operon genes is repressed by glucose and the repression is usually mediated by a
catabolite control protein A (CcpA) or ArcR, the transcriptional regulators belonging to the Crp/Fnr
family [40,56,59], by the binding of regulatory proteins to the cis-acting catabolite response elements
(cre) located in the promoter regions [61]. Moreover, bacteria have to survive and inhabit diverse
environmental niches or hosts, so they have complex regulatory mechanisms to sense and respond
to different environmental stresses; for example, it has been shown that the expression of the ADI
pathway of S. suis and L. hongkongensis occurs at varied temperatures, allowing better adaptation and
survival in different environments [52,62].
2.2.3. The Relationship between the ADI Pathway and Bacterial Pathogenesis
Due to the great importance of arginine metabolic functions, the ADI pathway has been
demonstrated to be necessary for bacterial survival under acidic conditions and important for
bacterial virulence in varied bacteria [14–17,56,63,64]. The ammonia produced by the ADI pathway
can neutralize the cytoplasmic pH and protect the cell from the potentially lethal effects of acidic
extracellular environments [15,16,65]. Furthermore, ADI was demonstrated to be required for
Streptococcus pyogenes to invade and survive inside epithelial cells, and necessary for the intracellular
survival of L. hongkongensis in macrophage cell lines [14,16]. Additionally, mutation of ADI gene has
been shown to reduce the survival of Listeria monocytogenes in the spleen of a mouse infection model [15].
Importantly, the ADI of Salmonella enterica serovar Typhimurium was recently established as a virulence
factor [17]. It was demonstrated that the expression of the ADI pathway genes of S. Typhimurium was
elevated after infecting macrophages cell lines, and disruption of ADI gene significantly reduced the
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bacterial replication in murine macrophages and attenuated the bacterial virulence in a mouse model,
when compared to the wild-type strain [17].
Although studied extensively, the precise mechanism by which the ADI pathway enhances
intracellular survival of bacteria and even their replication within macrophages is still unclear [16].
However, it is believed that there is some connection between phagocytosis and the ADI
pathway [16,17,66]. As an important defense strategy in innate immunity, phagocytosis has always
been employed by our immune system to initiate the innate immune response and destroy infectious
microorganisms [67]. In the process of phagocytosis, bacteria are enclosed in the phagosome [68,69],
which would undergo maturation and fuse with the lysosome, to form the phagolysosome [70], where
the pH drops as low as 4.4–4.7 [71–74]. Since the ADI pathway has the property of increasing the
cytoplasmic pH, it would be employed to protect bacteria from the potentially lethal effect of acidic
extracellular environments [15]. The ADI pathway can also protect bacteria from being killed in
the phagolysosome, via arresting the pH decrease (Figure 2), thereby preventing the phagosome
and lysosome from fusing. Bacteria ingested by phagocytes can be degraded in phagolysosomes in
different ways, including proteolytic enzymes like lysozymes, cationic proteins, and production of
antimicrobial products [17,75]. Of these antimicrobials, NO is synthesized from arginine by iNOS, and
the availability of arginine is one of the rate-limiting factors for intracellular NO production [76–78].
As the ADI pathway consumes arginine as a substrate, it appears that bacteria can use the ADI pathway
to exhaust arginine in the host cell. This will reduce NO production, avoid NO-mediated killing in the
phagocytes, and increase bacterial survival (Figure 2). However, a study on S. Typhimurium excluded
this possibility as the wild-type and ADI mutant strains have similar levels of NO production after
infection in macrophages [17]. More studies are needed to investigate other mechanisms in further
bacteria [2]. Remarkably, recombinant ADI (rADI) protein was employed as the neuroprotective protein
and was capable of blocking iNOS-induced NO production in neuronal cells as the neuroprotective
protein [79]; whether pathogenic bacteria would employ this strategy to escape from phagocytosis
killing warrants further investigation. There could also be many other possibilities. For example,
one proposed strategy is that the production of ATP in the process of ADI pathway enables bacteria
to provide energy for F1FO-ATPase to pump cytoplasmic protons and so maintain cytosolic pH
homeostasis under acidic environments. Similar strategies have been employed by many pathogenic
bacteria to survive within acidified phagosomes [80–83].
3. Arginine Metabolism and Cancer Therapy
Disorder of cellular metabolism has been accepted as one of the critical marks for cancer
production and expansion [3,4]; this has stimulated research on cancer metabolism and both the
basic science and clinical treatment of cancer [3,84]. The metabolic differences between normal cells
and tumor cells have provided opportunities for developing novel approaches for the diagnosis and
treatment of cancer with higher specificity and lower toxicity than conventional cancer therapies like
radiation and chemotherapy [4,85,86]. Of note, it is becoming clear that amino acid metabolic pathways
could be chemotherapeutic targets for cancer therapy, as cancer cells need abnormal quantities of
varied amino acids for their distinct metabolism to maintain high proliferative rates and resist some
cell death signals [87]. Consequently, the deprivation of amino acids needed by cancer cells to survive
has been recognized in the field of cancer therapy for a long time [5], especially for some cancers that
are auxotrophic for specific non-essential amino acids [4,6].
3.1. Arginine Deprivation and Cancer Therapy
The relationship between arginine and cancer has been recognized for many years [88]. Generally,
de novo biosynthesis of arginine is from the precursor argininosuccinate, which in turn is produced
from citrulline; this is facilitated by the enzymes argininosuccinate lyase (ASL) and ASS, respectively
(Figure 3) [4,89]. ASS is the rate-limiting biosynthetic enzyme for intracellular arginine synthesis in
different cells [86,89]; however, in some tumor cells it is reduced or even absent, like hepatocellular
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carcinoma (HCC), mesotheliomas, renal cell carcinoma, prostate cancers, and the majority of
melanoma [90–92] (Table 2). These ASS-negative tumor cells are auxotrophic (dependent on uptake
of extracellular arginine) for arginine and thus are very sensitive to arginine deprivation [4,85,89].
The clinical relevance of arginine metabolism in cancers was illustrated by the association of reduced
ASS and more aggressive clinical behavior in pancreatic cancer [93]. In addition, evaluation of ASS1
levels in clinical samples of acute myeloid leukemia is deemed a promising direction for identifying
patients who would be more sensitive to arginine deprivation therapy [94]. Consequently, arginine
deprivation by arginine-degrading enzymes has been used as a therapy for selective tumor cell
death while not harming normal cells [89]. However, only ADI and arginase are the commonly
investigated arginine-degrading enzymes in basic and clinical research. This is because the other
arginine-degrading enzymes have limitations, such as low affinity with arginine, higher optimal pH,
and poor stability [6,85,88].
Table 2. Common cancer cells with reduced or absent ASS production.
Cancer Cell Types Source or Reference
Melanoma [5,85,90,93,95–100]
Breast cancer cells [89]
Prostate cancer cells [4,86,90,101,102]
Lymphoma [89,103,104]
Hepatocellular carcinoma (HCC) [5,90,93,98,100,105–107]
Pancreatic cancer cells [91,93,108]
Leukemia [94,109–111]
Glioma [89,112]
Mesothelioma cell lines [5,113]
Renal cell carcinoma [4,93,114]
Lung cancer [93,115]
Arginase is responsible for hydrolyzing arginine to ornithine, which in turn can be converted to
citrulline by Ornithine carbamoyl transferase (OCT), thereby depleting the arginine in the arginine
auxotrophic cancer cells (Figures 1 and 3). There are two subtypes of arginase in humans (arginase I
and arginase II). Arginase I is mainly found in the liver and is considered the more efficient subtype and
used more commonly in research [6]. Compared with the arginase of bacteria, the arginase from human
sources has the advantage of low immunogenicity for use in vivo. However, it has been observed to
have a low affinity with arginine in vitro [4] and requires a higher pH than physiological conditions for
optimal activity (up to 9.5) [116], which limits its clinical effectiveness in cancer therapy. To overcome
these, recombinant human arginase (rhArg-PEG) has been produced by linking polyethylene glycol
(PEG) to the arginase, which increases its affinity with arginine and improves the half-life in vivo [117].
In addition, the replacement of Mn2+ with Co2+ in the active site of arginase can reduce the optimal
pH of recombinant human arginase (rhArg1) to as low as 7.5 and this metal ion replacement also
enhances rhArg1 cytotoxicity in hepatoma cancer cell lines [118]. Recently, other recombinant human
arginase (rhArg1-Fc) has been produced by ligating Fc fragment of human IgG1 to arginase I; this
greatly increases the half-life, inhibits cell proliferation, and impairs cellular migration of different
tumor cell lines both in vitro and in vivo [6,119].
Arginine deiminase is another well-studied arginine-depriving enzyme and this degrades arginine
to citrulline, which can be recycled back to arginine by ASS and ASL in many cell types but not in
ASS-negative cancer cells (Figure 3) [88,120]. The application of ADI for anti-tumor therapy in cancer
cell lines and animal models was demonstrated over two decades ago [121,122]. As ADI is not produced
in mammals, ADI protein for research is most commonly derived from Mycoplasma arginini [6].
However, because of its short half-life and high antigenicity, ADI is linked with PEG (ADI-PEG20)
and has been used for research and clinical use [4,123]. This has been observed to have significantly
reduced antigenicity, increased half-life [123], and high affinity with arginine (about 300-fold that
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of arginase under physiological pH) [85,101,124]. Because of its efficacy, it has been widely used in
clinical trials for anti-cancer treatment [105,106,125]. Of note, a recent study of neuroblastoma cells has
shown ADI-PEG20 to have potential for treating iNOS-mediated neurodegenerative diseases [126].
Importantly, it was reported that ADI-PEG20 treatment in mesothelioma patients can produce
anti-ADI-PEG20 neutralizing antibodies by the fourth week, thereby resisting drug usage; further
drug optimization is still needed to reduce ADI treatment’s immunogenicity, replace it with human
recombinant arginase I, and combine with various drugs [3,127,128].
3.2. Molecular Mechanisms of Arginine Depletion for Cancer Therapy
3.2.1. Arginine Deprivation Induces Autophagy in ASS-negative Cells
Arginine is an essential amino acid in ASS-negative tumor cells (Table 2) as these arginine
auxotrophic cells lack the ASS enzyme (Figure 3) responsible for generating arginine from citrulline
and therefore have to uptake extracellular arginine. It has been demonstrated that arginine depletion
in these cells causes nutritional deprivation and consequently induces autophagy, so that application
of arginine deprivation enzymes has been undertaken for cancer therapy [5,85,101]. Autophagy is a
highly regulated cellular pathway in which the constituents are sequestrated into double-membrane
compartments (known as autophagosomes) and fused with lysosomes for degradation [129–131]. This
process is the principal catabolic pathway to nutrient starvation [86,89,129,132]. Autophagy can be
activated by a range of pathways, one of which is the mTOR pathway.
During nutritional deprivation, the mTOR pathway is inhibited; this in turn inactivates some of the
non-essential energy consuming intracellular processes to preserve cell viability. This protective process
is an extensively investigated pathway for activating autophagy and can be triggered by arginine
depletion [5,85,101]. ADI treatment can cause arginine deprivation of tumor cells, which in turn
activates AMP-activated protein kinase (AMPK) [5,101]. This molecule is recognized to inhibit mTOR
activity via energy/nutrient sensing [109,133,134] (Figure 3) and so induce autophagy. Furthermore,
the activated AMPK induced by ADI treatment could also activate the MEK-ERK pathway, which has
been reported to be involved in autophagy by regulating Beclin 1 via noncanonical pathway [135],
suggesting that the MEK-ERK signaling pathway was also activated to induce autophagy by arginine
depletion [85,101]. Together, arginine deprivation by ADI treatment in ASS-negative cancer cells
activates AMPK, which further represses the mTOR activation and stimulates the MEK-ERK pathway,
thereby inducing autophagy activation. This is a survival strategy for cancer cells as the limited
arginine can be recycled and provide protection for other cells [85].
Apart from autophagy, arginine metabolism was demonstrated to modulate chemosensitivity of
cancer cells. In particular, ADI reinforced the effects of gemcitabine on pancreatic cancer cells [93].
This was achieved through regulation of cell cycle progression, the caspase system, as well as the
NF-κB pathway.
3.2.2. Arginine Deprivation Prompts Cell Death in ASS-negative Cells
Arginine deprivation has also been reported to induce apoptosis and cause cell death in
ASS-negative tumor cell lines, including human lymphoblastic cell lines, mesothelioma cells, melanoma
cell lines, prostate cancer cell lines, and breast cancer [5,89,95,101,113,136,137]. Although the signaling
pathway responsible for apoptosis is still not clear, it is recognized that the apoptosis induced by
arginine deprivation could be activated via caspase-dependent and/or independent pathways [85,102].
Szlosarek et al. showed that arginine depletion in ASS-negative mesothelioma cells induced apoptosis
via Bcl-2-associated X protein (BAX) activation and mitochondrial inner membrane depolarization [113].
Importantly, excessive autophagy could be cytotoxic and also cause cell death (program type II
or caspase-independent cell death) [86,89,138]. Kim et al. observed that autophagy induced by
arginine depletion in ASS-negative cells could lead to apoptotic cell death in a caspase-independent
manner at four days after ADI treatment [101]. In ASS1-deficient breast cancer cells, prolonged
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autophagy activated by ADI treatment impaired mitochondrial bioenergetics and integrity by inducing
mitochondrial oxidative stress, and finally caused cell death, indicating the relationship of the cytotoxic
autophagy arisen by mitochondrial dysfunction with cell death [89]. Furthermore, Changou et al.
observed that mitochondrial damage played a central role in new atypical cell death induced by
arginine starvation in the late phase of autophagy. This can lead to reactive oxygen species generation,
DNA leakage, chromatin autophagy, and finally cell death [86]. Remarkably, the recombinant human
arginase (rhArg) treatment restrains the proliferation of mammalian melanoma in vitro and in vivo and
causes cell death induced by apoptosis [96]. The reason why rhArg affects cell proliferation is that the
rhArg can induce the cell cycle arrest at both of G2/M and S phase. Similarly to arginine depletion
caused by ADI treatment, the cell cycle arrest caused by rhArg also upregulates the caspase expression,
thereby inducing apoptosis [96].
The processes of autophagy and apoptosis are related in ASS-negative cells. In the early stage of
nutrient deficiency, autophagy will be triggered to recycle limited arginine and preserve the tumor
cell and this will have an inhibitory effect on apoptosis. However, when the cells undergo arginine
depletion for a longer time and autophagy cannot provide arginine anymore, the cells will undergo
caspase-independent apoptosis. Meanwhile, caspase-dependent apoptosis could also be activated by
ADI treatment via some other signaling pathways, for example BAX activation (Figure 3). In addition
to the arginine deprivation-caused cell death by autophagy and apoptosis pathways, cell death
induced by necrosis was also observed in acute myeloid leukemia (AML) treated with pegylated (PEG)
recombinant human arginase (BCT-100) [110]. BCT-100 treatment in AML was observed to reduce the
arginine concentration (in vitro and intracellular) and AML blasts. Furthermore, the arginine depletion
of BCT-100 treatment significantly arrested AML proliferation and the cell cycle, resulting in cell death
of necrosis, including cell membrane permeabilization and organelle enlargement [110]. Interestingly,
the cell cycle arrest in AML did not induce cell apoptosis, autophagy, and rapid production of reactive
oxygen species.
4. Conclusions
Our recent findings on the biochemical pathways of arginine metabolism and their regulation
in bacteria and cancer cells have not only improved our knowledge of the pathogenesis of bacterial
pathogens and cancer metabolism, but may also result in specific anti-bacterial and anti-cancer
therapies. Further work in these areas is warranted to improve our armory of strategies against
these two common groups of diseases affecting human health.
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